Navigation Links
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
Date:5/19/2008

ies Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated future financial results and product development. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (ii) risks related to achieving positive clinical trial results; (iii) the results of the InterMune CAPACITY trials of pirfenidone may differ materially from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone in Japan; (iv) the designation of pirfenidone for Fast Track status by the FDA does not guarantee that the FDA will grant Priority Review of the NDA filed by InterMune in connection with the approval of pirfenidone for the treatment of IPF in the United States. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Progress on Pirfenidone in IPF
2. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Announces Start of Phase 1b Trial of ITMN-191
5. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
6. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
7. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
8. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
9. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
10. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
11. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Md., June 01, 2007 /PRNewswire-FirstCall/ --,EntreMed, Inc. ... the treatment of cancer and inflammatory diseases,announced ... Aurora,kinase - angiogenesis inhibitor, ENMD-981693. The data ... EntreMed,scientists at the 2nd Protein Kinases in ...
... Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. ... ongoing clinical,studies of SNS-595 and SNS-032 at the ... held June 7-10, 2007 in Vienna,Austria. , Presentations ... 1 clinical trial of SNS-595 in acute leukemias, ...
Cached Medicine Technology:EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 2EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 3Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3
(Date:7/11/2014)... Cancer researchers in Slovenia say genetic variations ... how patients respond to treatment with pemetrexed (Alimta), the ... the full story. Click here to read the ... of Ljubljana and the Ljubljana Institute of Oncology tested ... of polymorphisms. They found that patients with genetic variations ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
(Date:7/11/2014)... Woodland Hills permanent teeth in one day ... Institute in Woodland Hills and Oxnard, Calif., will speak next ... Rey, Calif. , The award-winning prosthodontist, international speaker and ... in one day dental procedure at 1:30 p.m. Friday, July ... 15 years ago, Dr. Jivraj said. Getting new teeth in ...
(Date:7/11/2014)... 11, 2014 BellasDress, the experienced dressmaker ... popular online suppliers when it comes to beach ... new collection of beach wedding outfits in its online ... of elegant outfits. , BellasDress has been considered ... world. According to the company’s senior spokesman, BellasDress provides ...
(Date:7/11/2014)... The International Concussion Organization is ... Best Buy Theater in Times Square, New York ... growing concussion epidemic that is plaguing athletes in ... competition. , The Symposium gathers more than a ... professional athletes and legal scholars for engaging and ...
Breaking Medicine News(10 mins):Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2
... statistically significant decline in prostate specific antigen (PSA) levels, ... issue of the Journal of the National Cancer ... was associated with a reduction in prostate cancer risk. ... examined the association between statins and PSA level. ...
... PAUL, Minn., Oct. 28 Dean Barkley,candidate for US Senate ... to fight HIV/AIDS in the US and around the world., ... candidates from,Minnesota will also agree to sign the pledge," said ... "The pledge helps,voters see who is prepared to take a ...
... (Nasdaq: AHII ) announced today that the Company ... quarter ended,September 30, 2008 on Tuesday, November 4, 2008. ... same day at 10:00 a.m.,Eastern Standard Time to discuss ... access the conference call by dialing (719) 785-1758.,Participants will ...
... drug delayed disease progression, researchers found , , WEDNESDAY, Oct. ... to treat erectile dysfunction, appears effective in treating pulmonary ... high blood pressure in the arteries that supply the ... can become tired, dizzy and short of breath, because ...
... INDIANAPOLIS, Oct. 28 WellPoint, Inc. (NYSE:,WLP) announced ... at the,following conferences:, -- Oppenheimer 19th Annual ... Eastern Standard Time ("EST"); and, -- 2008 ... at,9:30 a.m. Mountain Standard Time (11:30 a.m. EST)., ...
... Corporation,(NYSE: DHR ) announced that Executive Vice ... be presenting at the Goldman Sachs Global,Industrials Conference ... 2008 at,8:00 a.m. EST. The audio will be ... Corporation is a leading manufacturer of Professional,Instrumentation, Medical ...
Cached Medicine News:Health News:Statin use associated with reduction in prostate specific antigen levels 2Health News:Senator Dean Barkley Pledges Action on HIV/AIDS Epidemic 2Health News:Cialis May Help Ease Pulmonary Hypertension 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2
... design facilitates negotiation of the prostatic ... medium length olive Coude tip with ... latex construction provides added stiffness and ... in a variety of materials, eye ...
Used to provide bladder drainage by percutaneous placement of a balloon catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used to provide bladder drainage by percutaneous placement of a Malecot catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used for pulling sutures from a vaginal incision into the suprapubic area during bladder suspension surgery. Supplied sterile in peel-open packages....
Medicine Products: